Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Oden6570on Jan 25, 2023 8:19am
293 Views
Post# 35244564

The 2023 ASCO Genitourinary Cancers Symposium

The 2023 ASCO Genitourinary Cancers Symposium

11:00 AM–12:30 PM

Innovations and Multidisciplinary Care in Early- and Late-Stage Urothelial Cancer

Next Generation Therapies in Nonmuscle-Invasive Bladder Cancer

Understanding Methods of BCG Unresponsive Nonmuscle-Invasive Bladder Cancer

Optimizing Survival for Patients With Muscle-Invasive Bladder Cancer

Radiation Therapy in Oligometastatic and Local Recurrence Urothelial Carcinoma: The What, Why, and How

Sequencing Systemic Therapies and Looking to the Horizon for Metastatic Urothelial Carcinoma

Moderated Panel Discussion

Program | ASCO Genitourinary Cancers Symposium
<< Previous
Bullboard Posts
Next >>